Latest news with #ASX200
AU Financial Review
an hour ago
- Business
- AU Financial Review
ASX to fall; investors fret Iran attack will upend long bull run
The price of oil will spike as markets open and could even soar beyond $US100 a barrel after the Trump administration's intervention into a weeks-long war between Israel and Iran unsettles financial markets. While the price of Brent crude has drifted more than 10 per cent higher since Israel first launched an attack on Iranian nuclear assets two weeks ago, traders fear US President Donald Trump's authorisation of bombing at the weekend will lead to a rapid escalation in the conflict. In particular, traders are worried that Iran could constrict travel through the Strait of Hormuz, a key shipping route for oil that connects the Persian Gulf and the Gulf of Oman. If this closes, prices could increase significantly, pushing inflation higher and disrupting expectations that central banks including the Reserve Bank of Australia will keep cutting rates. 'For markets, this shatters the illusion of containment. What was a regional proxy conflict is now a high-stakes, US-driven air war targeting [weapons of mass destruction] infrastructure – with unpredictable spillovers across energy markets, global shipping lanes, and risk sentiment,' wrote SPI Asset Management's Stephen Innes of the bombing of nuclear facilities. 'This is no longer a waiting game – it's a market moment that demands positioning, not passivity,' he said in his Dark Side of the Boom newsletter. The S&P/ASX 200 is priced to open 0.2 per cent lower on Monday, although those futures were set before the weekend strikes. Wall Street had ended the last week mostly lower, although traders had hedged their bets and markets had remained largely flat for days. The S&P fell 0.2 per cent, while the Dow and the Nasdaq rose 0.1 per cent and 0.2 per cent respectively. The ASX 200 eased 0.5 per cent last week, the first weekly drop in three months.
Yahoo
3 hours ago
- Business
- Yahoo
ASX Dividend Stocks To Watch In June 2025
As global tensions and economic uncertainties weigh on markets, the ASX 200 is expected to open slightly lower, reflecting broader concerns over potential geopolitical developments and their impact on investor sentiment. In this environment, dividend stocks can offer a measure of stability through regular income streams, making them an attractive option for investors seeking resilience amid market volatility. Name Dividend Yield Dividend Rating Sugar Terminals (NSX:SUG) 8.37% ★★★★★☆ Nick Scali (ASX:NCK) 3.31% ★★★★★☆ New Hope (ASX:NHC) 9.87% ★★★★★☆ MFF Capital Investments (ASX:MFF) 3.74% ★★★★★☆ Lycopodium (ASX:LYL) 7.35% ★★★★★☆ Lindsay Australia (ASX:LAU) 7.05% ★★★★★☆ IPH (ASX:IPH) 7.66% ★★★★★☆ Fiducian Group (ASX:FID) 4.80% ★★★★★☆ Bisalloy Steel Group (ASX:BIS) 9.85% ★★★★★☆ Accent Group (ASX:AX1) 9.70% ★★★★★☆ Click here to see the full list of 29 stocks from our Top ASX Dividend Stocks screener. Let's uncover some gems from our specialized screener. Simply Wall St Dividend Rating: ★★★★★☆ Overview: Bisalloy Steel Group Limited manufactures and sells quenched and tempered, high-tensile, and abrasion-resistant steel plates in Australia, Indonesia, Thailand, and internationally with a market cap of A$156.59 million. Operations: Bisalloy Steel Group Limited generates revenue through the production and distribution of high-performance steel plates, including quenched and tempered, high-tensile, and abrasion-resistant varieties across various international markets. Dividend Yield: 9.8% Bisalloy Steel Group offers a compelling dividend yield of 9.85%, placing it in the top 25% of Australian dividend payers. However, its dividends have been volatile and unreliable over the past decade, with significant annual drops. Despite this instability, recent earnings growth of 14% and sustainable payout ratios—81.2% from earnings and 66.6% from cash flows—suggest current dividends are covered. The stock trades at good value relative to peers and industry estimates, enhancing its appeal for income-focused investors seeking high yields amidst volatility concerns. Navigate through the intricacies of Bisalloy Steel Group with our comprehensive dividend report here. The valuation report we've compiled suggests that Bisalloy Steel Group's current price could be quite moderate. Simply Wall St Dividend Rating: ★★★★★☆ Overview: Lycopodium Limited offers engineering and project delivery services across the resources, rail infrastructure, and industrial processes sectors in Australia, with a market cap of A$407.25 million. Operations: Lycopodium Limited's revenue is primarily derived from its resources segment, which generated A$347.83 million, with additional contributions of A$10.84 million from process industries and A$10.14 million from rail infrastructure sectors. Dividend Yield: 7.4% Lycopodium's dividend yield of 7.35% ranks in the top 25% of Australian payers, yet its past decade has seen volatility and unreliability with annual drops over 20%. Despite this, dividends are well-covered by earnings (43.2%) and cash flows (80.8%). The stock is trading at a discount to its estimated fair value, offering potential value for investors. Recent board changes with Rob Radici's appointment may influence strategic direction amidst industry expertise in major projects. Click to explore a detailed breakdown of our findings in Lycopodium's dividend report. Insights from our recent valuation report point to the potential undervaluation of Lycopodium shares in the market. Simply Wall St Dividend Rating: ★★★★☆☆ Overview: Medibank Private Limited operates as a provider of private health insurance and health services in Australia, with a market capitalization of A$13.44 billion. Operations: Medibank Private Limited generates revenue primarily from its Health Insurance segment, which accounts for A$8.06 billion, and its Medibank Health segment, contributing A$447.10 million. Dividend Yield: 3.4% Medibank Private's dividend yield of 3.4% is below the top 25% in Australia and not well covered by earnings, with a high payout ratio of 96.7%. However, dividends have been stable and reliable over the past decade, supported by cash flows with an 82.6% cash payout ratio. Despite recent legal challenges related to a cybercrime event, Medibank trades at a discount to its estimated fair value, potentially offering value for investors seeking stability amidst growth prospects. Click here to discover the nuances of Medibank Private with our detailed analytical dividend report. According our valuation report, there's an indication that Medibank Private's share price might be on the expensive side. Click through to start exploring the rest of the 26 Top ASX Dividend Stocks now. Are these companies part of your investment strategy? Use Simply Wall St to consolidate your holdings into a portfolio and gain insights with our comprehensive analysis tools. Elevate your portfolio with Simply Wall St, the ultimate app for investors seeking global market coverage. Explore high-performing small cap companies that haven't yet garnered significant analyst attention. Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management. Find companies with promising cash flow potential yet trading below their fair value. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include ASX:BIS ASX:LYL and ASX:MPL. This article was originally published by Simply Wall St. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@
Yahoo
3 hours ago
- Business
- Yahoo
ASX Dividend Stocks To Watch In June 2025
As global tensions and economic uncertainties weigh on markets, the ASX 200 is expected to open slightly lower, reflecting broader concerns over potential geopolitical developments and their impact on investor sentiment. In this environment, dividend stocks can offer a measure of stability through regular income streams, making them an attractive option for investors seeking resilience amid market volatility. Name Dividend Yield Dividend Rating Sugar Terminals (NSX:SUG) 8.37% ★★★★★☆ Nick Scali (ASX:NCK) 3.31% ★★★★★☆ New Hope (ASX:NHC) 9.87% ★★★★★☆ MFF Capital Investments (ASX:MFF) 3.74% ★★★★★☆ Lycopodium (ASX:LYL) 7.35% ★★★★★☆ Lindsay Australia (ASX:LAU) 7.05% ★★★★★☆ IPH (ASX:IPH) 7.66% ★★★★★☆ Fiducian Group (ASX:FID) 4.80% ★★★★★☆ Bisalloy Steel Group (ASX:BIS) 9.85% ★★★★★☆ Accent Group (ASX:AX1) 9.70% ★★★★★☆ Click here to see the full list of 29 stocks from our Top ASX Dividend Stocks screener. Let's uncover some gems from our specialized screener. Simply Wall St Dividend Rating: ★★★★★☆ Overview: Bisalloy Steel Group Limited manufactures and sells quenched and tempered, high-tensile, and abrasion-resistant steel plates in Australia, Indonesia, Thailand, and internationally with a market cap of A$156.59 million. Operations: Bisalloy Steel Group Limited generates revenue through the production and distribution of high-performance steel plates, including quenched and tempered, high-tensile, and abrasion-resistant varieties across various international markets. Dividend Yield: 9.8% Bisalloy Steel Group offers a compelling dividend yield of 9.85%, placing it in the top 25% of Australian dividend payers. However, its dividends have been volatile and unreliable over the past decade, with significant annual drops. Despite this instability, recent earnings growth of 14% and sustainable payout ratios—81.2% from earnings and 66.6% from cash flows—suggest current dividends are covered. The stock trades at good value relative to peers and industry estimates, enhancing its appeal for income-focused investors seeking high yields amidst volatility concerns. Navigate through the intricacies of Bisalloy Steel Group with our comprehensive dividend report here. The valuation report we've compiled suggests that Bisalloy Steel Group's current price could be quite moderate. Simply Wall St Dividend Rating: ★★★★★☆ Overview: Lycopodium Limited offers engineering and project delivery services across the resources, rail infrastructure, and industrial processes sectors in Australia, with a market cap of A$407.25 million. Operations: Lycopodium Limited's revenue is primarily derived from its resources segment, which generated A$347.83 million, with additional contributions of A$10.84 million from process industries and A$10.14 million from rail infrastructure sectors. Dividend Yield: 7.4% Lycopodium's dividend yield of 7.35% ranks in the top 25% of Australian payers, yet its past decade has seen volatility and unreliability with annual drops over 20%. Despite this, dividends are well-covered by earnings (43.2%) and cash flows (80.8%). The stock is trading at a discount to its estimated fair value, offering potential value for investors. Recent board changes with Rob Radici's appointment may influence strategic direction amidst industry expertise in major projects. Click to explore a detailed breakdown of our findings in Lycopodium's dividend report. Insights from our recent valuation report point to the potential undervaluation of Lycopodium shares in the market. Simply Wall St Dividend Rating: ★★★★☆☆ Overview: Medibank Private Limited operates as a provider of private health insurance and health services in Australia, with a market capitalization of A$13.44 billion. Operations: Medibank Private Limited generates revenue primarily from its Health Insurance segment, which accounts for A$8.06 billion, and its Medibank Health segment, contributing A$447.10 million. Dividend Yield: 3.4% Medibank Private's dividend yield of 3.4% is below the top 25% in Australia and not well covered by earnings, with a high payout ratio of 96.7%. However, dividends have been stable and reliable over the past decade, supported by cash flows with an 82.6% cash payout ratio. Despite recent legal challenges related to a cybercrime event, Medibank trades at a discount to its estimated fair value, potentially offering value for investors seeking stability amidst growth prospects. Click here to discover the nuances of Medibank Private with our detailed analytical dividend report. According our valuation report, there's an indication that Medibank Private's share price might be on the expensive side. Click through to start exploring the rest of the 26 Top ASX Dividend Stocks now. Are these companies part of your investment strategy? Use Simply Wall St to consolidate your holdings into a portfolio and gain insights with our comprehensive analysis tools. Elevate your portfolio with Simply Wall St, the ultimate app for investors seeking global market coverage. Explore high-performing small cap companies that haven't yet garnered significant analyst attention. Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management. Find companies with promising cash flow potential yet trading below their fair value. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include ASX:BIS ASX:LYL and ASX:MPL. This article was originally published by Simply Wall St. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@ Sign in to access your portfolio
Yahoo
3 hours ago
- Business
- Yahoo
Pro Medicus And 2 Other High Growth Tech Stocks In Australia
In the current Australian market landscape, the ASX 200 futures are indicating a slight dip of -0.2% amid geopolitical tensions and mixed economic signals, while unemployment remains stable at 4.1%. Against this backdrop, high growth tech stocks like Pro Medicus are garnering attention for their potential to thrive in uncertain conditions by leveraging innovation and adaptability to navigate market challenges. Name Revenue Growth Earnings Growth Growth Rating Gratifii 42.14% 113.99% ★★★★★★ Pro Medicus 22.19% 23.49% ★★★★★★ WiseTech Global 20.15% 25.52% ★★★★★★ Wrkr 56.40% 116.83% ★★★★★★ AVA Risk Group 29.15% 108.15% ★★★★★★ Echo IQ 61.50% 65.86% ★★★★★★ BlinkLab 65.54% 64.35% ★★★★★★ Immutep 70.42% 42.39% ★★★★★☆ Adveritas 52.34% 88.83% ★★★★★★ SiteMinder 19.89% 69.58% ★★★★★☆ Click here to see the full list of 47 stocks from our ASX High Growth Tech and AI Stocks screener. Let's dive into some prime choices out of from the screener. Simply Wall St Growth Rating: ★★★★★★ Overview: Pro Medicus Limited is a healthcare informatics company that develops and supplies imaging software and radiology information system services to hospitals, imaging centers, and healthcare groups across Australia, North America, and Europe, with a market cap of A$28.92 billion. Operations: Pro Medicus Limited generates revenue primarily through the production of integrated software applications for the healthcare industry, totaling A$184.58 million. The company's operations span Australia, North America, and Europe, focusing on imaging software and radiology information systems for medical facilities. Pro Medicus, a standout in the Australian tech landscape, exemplifies robust growth with its revenue and earnings forecast to expand at 22.2% and 23.5% per annum respectively, significantly outpacing the broader market's expectations. This performance is bolstered by strategic share repurchases, with a recent buyback of 28,326 shares for AUD 6.35 million enhancing shareholder value. Additionally, inclusion in the S&P International 700 and Global 1200 indices not only underscores its market relevance but also augments its visibility among global investors. The company's commitment to innovation is evident from its R&D initiatives aimed at advancing healthcare technology solutions—a sector witnessing rapid growth due to increasing demand for efficient medical services. Navigate through the intricacies of Pro Medicus with our comprehensive health report here. Explore historical data to track Pro Medicus' performance over time in our Past section. Simply Wall St Growth Rating: ★★★★☆☆ Overview: SEEK Limited operates as an online employment marketplace service provider across Australia, South East Asia, New Zealand, the United Kingdom, Europe, and other international markets with a market cap of A$8.55 billion. Operations: The company generates revenue primarily through its employment marketplace services, with A$821.40 million from the ANZ region and A$240.90 million from Asia. Amidst a challenging landscape, SEEK has demonstrated resilience with its revenue and earnings poised for significant growth. Despite a substantial one-off loss of A$119.8 million last year, the company's revenue is expected to rise by 9.1% annually, outpacing the Australian market's growth of 5.6%. Furthermore, SEEK's earnings are forecasted to surge by 25.9% per year, notably higher than the market average of 11.6%. This robust financial outlook is underpinned by strategic initiatives and an Analyst/Investor Day that highlighted future prospects, reinforcing SEEK's potential in a competitive sector. Unlock comprehensive insights into our analysis of SEEK stock in this health report. Understand SEEK's track record by examining our Past report. Simply Wall St Growth Rating: ★★★★★☆ Overview: Telix Pharmaceuticals Limited is a commercial-stage biopharmaceutical company that develops and commercializes therapeutic and diagnostic radiopharmaceuticals for cancer and rare diseases, with a market cap of A$8.43 billion. Operations: Telix Pharmaceuticals generates revenue primarily from its Precision Medicine segment, which accounts for A$771.11 million, while its Therapeutics and Manufacturing Solutions segments contribute A$9.35 million and A$2.75 million, respectively. Telix Pharmaceuticals has demonstrated a robust trajectory in the high-growth tech sector, particularly through its innovative approaches in prostate cancer imaging. With a staggering annual earnings growth of 858% last year and an expected annual revenue increase of 19.8%, Telix outpaces the Australian market's average growth significantly. Recent strategic product launches, like the AlFluor™ platform and Illuccix®, have not only expanded its portfolio but also fortified its market position by enhancing diagnostic precision and treatment efficacy in oncology. These developments underscore Telix's commitment to advancing healthcare technology, positioning it well for sustained growth amidst evolving medical demands. Delve into the full analysis health report here for a deeper understanding of Telix Pharmaceuticals. Gain insights into Telix Pharmaceuticals' past trends and performance with our Past report. Click here to access our complete index of 47 ASX High Growth Tech and AI Stocks. Have you diversified into these companies? Leverage the power of Simply Wall St's portfolio to keep a close eye on market movements affecting your investments. Enhance your investing ability with the Simply Wall St app and enjoy free access to essential market intelligence spanning every continent. Explore high-performing small cap companies that haven't yet garnered significant analyst attention. Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management. Find companies with promising cash flow potential yet trading below their fair value. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include ASX:PME ASX:SEK and ASX:TLX. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@
Yahoo
3 hours ago
- Business
- Yahoo
Undiscovered Gems In Australia To Watch This June 2025
As global markets react to geopolitical tensions and economic uncertainties, the Australian market is experiencing a slight downturn, with ASX 200 futures indicating a modest decline amid broader concerns impacting international indices. In this climate of caution, identifying promising small-cap stocks requires a focus on companies that demonstrate strong fundamentals and resilience in navigating volatile conditions. Name Debt To Equity Revenue Growth Earnings Growth Health Rating Sugar Terminals NA 3.78% 4.30% ★★★★★★ Schaffer 25.47% 6.03% -5.20% ★★★★★★ Fiducian Group NA 9.97% 7.85% ★★★★★★ Hearts and Minds Investments NA 47.09% 49.82% ★★★★★★ Djerriwarrh Investments 1.14% 8.17% 7.54% ★★★★★★ Red Hill Minerals NA 95.16% 40.06% ★★★★★★ MFF Capital Investments 0.69% 28.52% 31.31% ★★★★★☆ Lycopodium 6.89% 16.56% 32.73% ★★★★★☆ Carlton Investments 0.02% 4.45% 3.97% ★★★★★☆ K&S 20.24% 1.58% 25.54% ★★★★☆☆ Click here to see the full list of 45 stocks from our ASX Undiscovered Gems With Strong Fundamentals screener. Below we spotlight a couple of our favorites from our exclusive screener. Simply Wall St Value Rating: ★★★★★☆ Overview: Diversified United Investment Limited is a publicly owned investment manager with a market capitalization of A$1.16 billion. Operations: The company's revenue primarily comes from its investment operations, generating A$46.41 million. Diversified United Investment, a smaller player in the market, showcases solid financial health with cash exceeding its total debt and a notably reduced debt-to-equity ratio from 8.2% to 0.9% over five years. The company's interest payments are well-covered by EBIT at 12.2 times, indicating strong earnings quality. Despite recent negative earnings growth of -7%, contrasting sharply with the industry average of 23.6%, DUI remains free cash flow positive and profitable, ensuring no immediate concerns about its cash runway. Recently, it extended its buyback plan until May 2026, suggesting confidence in future performance despite current challenges. Unlock comprehensive insights into our analysis of Diversified United Investment stock in this health report. Review our historical performance report to gain insights into Diversified United Investment's's past performance. Simply Wall St Value Rating: ★★★★★★ Overview: Hearts and Minds Investments (ASX:HM1) is an Australian investment company with a market cap of A$686.95 million, focusing on generating superior returns through a concentrated portfolio of high-conviction stocks selected by leading fund managers. Operations: Hearts and Minds Investments generates revenue primarily from investment activities, amounting to A$191.25 million. The company's financial performance is influenced by its net profit margin trends, which reflect the efficiency of its investment strategy and cost management. Hearts and Minds Investments, a relatively small player in the Australian market, showcases impressive earnings growth of 466% over the past year, significantly outpacing the Capital Markets industry average of 23%. With no debt on its books for five years, it sidesteps concerns over interest payments. The company's Price-To-Earnings ratio stands at an attractive 5.4x compared to the broader Australian market's 17.9x. Despite not being free cash flow positive recently, its high level of non-cash earnings suggests robust underlying quality in its financials. Click here and access our complete health analysis report to understand the dynamics of Hearts and Minds Investments. Examine Hearts and Minds Investments' past performance report to understand how it has performed in the past. Simply Wall St Value Rating: ★★★★★☆ Overview: Lycopodium Limited is an Australian company offering engineering and project delivery services across the resources, rail infrastructure, and industrial processes sectors, with a market capitalization of A$407.25 million. Operations: Lycopodium generates revenue primarily from its resources segment, contributing A$347.83 million, while the process industries and rail infrastructure segments add A$10.84 million and A$10.14 million, respectively. Lycopodium, a relatively smaller player in the engineering sector, is trading at 19.1% below its estimated fair value, suggesting potential upside. Despite a negative earnings growth of 19.3% over the last year compared to the construction industry's average of 28.7%, it remains free cash flow positive with A$30.77M reported recently. This company has more cash than total debt, indicating strong financial health despite its debt-to-equity ratio increasing to 6.9% over five years. Recently appointed Non-Executive Director Rob Radici brings valuable experience from major projects across multiple sectors, potentially enhancing strategic direction and future project delivery capabilities for Lycopodium. Delve into the full analysis health report here for a deeper understanding of Lycopodium. Understand Lycopodium's track record by examining our Past report. Investigate our full lineup of 45 ASX Undiscovered Gems With Strong Fundamentals right here. Got skin in the game with these stocks? Elevate how you manage them by using Simply Wall St's portfolio, where intuitive tools await to help optimize your investment outcomes. Elevate your portfolio with Simply Wall St, the ultimate app for investors seeking global market coverage. Explore high-performing small cap companies that haven't yet garnered significant analyst attention. Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management. Find companies with promising cash flow potential yet trading below their fair value. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include ASX:DUI ASX:HM1 and ASX:LYL. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
